111 Capital Invests $1.71 Million in Vertex Pharmaceuticals

Pharmaceutical company sees large institutional investor take new position

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

111 Capital, a large investment firm, has purchased 4,363 shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) valued at approximately $1.71 million. This represents a new position for 111 Capital in the Boston-based biotech company known for its work in cystic fibrosis treatments.

Why it matters

Vertex Pharmaceuticals is a prominent pharmaceutical company focused on developing innovative therapies for serious diseases. The investment by 111 Capital signals confidence in Vertex's future growth potential and the value of its drug pipeline, particularly its cystic fibrosis treatments that have transformed standards of care for many patients.

The details

According to a recent SEC filing, 111 Capital bought the new position in Vertex Pharmaceuticals during the third quarter of 2026. The 4,363 shares purchased are valued at around $1.709 million. This represents a new investment for 111 Capital in the Boston-based biotech firm.

  • 111 Capital purchased the Vertex Pharmaceuticals shares in the 3rd quarter of 2026.

The players

111 Capital

A large investment firm that has taken a new position in Vertex Pharmaceuticals.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

Vertex Pharmaceuticals' innovative drug pipeline, particularly its cystic fibrosis treatments, continue to attract significant investment interest from major institutional investors like 111 Capital. This signals confidence in the company's future growth potential as it works to address unmet medical needs.